MedTrace Logo

HIV Prevention and Care Interventions for Youth in Uganda

NCT06474364 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2025-07-29

No results posted yet for this study

Summary

Several studies show that Adolescents and Young Adults (AYA) have poor outcomes along the entire Human Immunodeficiency Virus (HIV) prevention and care cascades compared to adults. The investigators propose to evaluate novel evidence-based HIV prevention and care interventions (including Cabotegravir LongActing (CABLA) to determine implementation outcomes among AYA who are at particularly high risk for HIV acquisition and poor viral suppression in five geographically distinct research performance sites in Uganda. The results will provide important evidence to inform Uganda and other regional countries' policy on integrated HIV prevention, care and treatment for AYA at high risk for HIV and Sexually Transmitted Infections (STIs) in order to reach the UNAIDS 95-95-95 targets and HIV epidemic control.

Conditions

Interventions

DRUG

Long-acting Cabotegravir injection

Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.

OTHER

SEARCH-YOUTH

It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.

Sponsors & Collaborators

  • Makerere University Joint AIDS Program

    collaborator OTHER

  • Infectious Diseases Research Collaboration, Uganda

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • MU-JHU CARE

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2028-08-31
Completion
2028-08-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06474364 on ClinicalTrials.gov